Clinical Trial Update: OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients. [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing two dosing regimens of CellCept (mycophenolate mofetil) in kidney transplant patients has completed and results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Kidney Transplantation | Phase 3 | Status: COMPLETED | Results posted: 2015-11-11